Intervention

Tolvaptan

ClinicalTrials.gov intervention label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 20 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials20
Recruiting0
Common conditions17
Lead sponsors shown15
Advertisement

Clinical trials

20 shown
A Study of HRS-9057 in Patients With Heart Failure and Volume OverloadNCT06506994 · 2024-08-16
COMPLETED
Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAHNCT05569655 · 2021-04-06
UNKNOWN
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume OverloadNCT03255226 · 2018-03-07
COMPLETED
Tolvaptan for Advanced or Refractory Heart FailureNCT02959411 · 2016-10-01
TERMINATED
Regional Tolvaptan RegistryNCT02666651 · 2016-05-01
UNKNOWN
Aquaresis Utility for Hyponatremic Acute Heart Failure StudyNCT02183792 · 2014-12-01
COMPLETED
Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart FailureNCT02352285 · 2012-12-01
TERMINATED
Tolvaptan for Hyponatremia in Cirrhotic Patients With AscitesNCT01716611 · 2012-11-01
UNKNOWN
Targeting Acute Congestion With Tolvaptan in Congestive Heart FailureNCT01644331 · 2012-10-01
COMPLETED
The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot StudyNCT01663662 · 2012-08-01
WITHDRAWN
Efficacy and Safety Study of Tolvaptan to Treat Patients With Cardiac EdemaNCT01651156 · 2012-07-01
COMPLETED
Efficacy and Safety of Tolvaptan in the Treatment of Cardiac-Induced Edema in Patients With Heart FailureNCT01618448 · 2012-07-01
COMPLETED
Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure PatientsNCT01439009 · 2011-09-01
COMPLETED
Tolvaptan for In-hospital HyponatremiaNCT01386372 · 2011-06-01
TERMINATED
Post-Authorisation Safety Study of Samsca (Tolvaptan) Used in Routine Medical PracticeNCT01228682 · 2010-10-01
UNKNOWN
Study of Ascending Levels of Tolvaptan in HyponatremiaNCT00201994 · 2003-11-01
COMPLETED
EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With TolvaptanNCT00071331 · 2003-09-01
COMPLETED
Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure PatientsNCT00043758 · 2002-07-01
COMPLETED
Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure PatientsNCT00043771 · 2002-05-01
COMPLETED
Acute Heart Failure Patients With High Copeptin Treated With Tolvaptan Targets Increased AVP Activation for Treatment (ACTIVATE)NCT01733134
WITHDRAWN

Leading sponsors

Trial status mix

COMPLETED11
UNKNOWN4
TERMINATED3
WITHDRAWN2

Phase mix

PHASE37
PHASE47
PHASE23
NA1
PHASE11
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.